Intrepid (INTermediate Risk Erection Preservation Trial:) A Randomized Phase II Trial of Radiation Therapy and Darolutamide for Prostate Cancer - (DF/HCC 19-202)
This research study is comparing the use of a new form of hormonal therapy used with radiation as a possible treatment for intermediate risk prostate cancer. More specifically, this research would help determine whether this new form of hormonal therapy is as effective as the standard hormone therapy while also preserving erectile function.
Anthony Gulati, MD
Sponsor(s)Dana-Farber Cancer Institute
ContactEd Hatton, RN at 203-358-8879 or [email protected]
Bennett Cancer Center
Stamford, CT 06902